Back
Open Access

A continuum of multifactorial benefits of icosapent ethyl.

Session: New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice
Topic: Lipid-Lowering Agents
Speaker: Professor M. Back (Stockholm, SE)
Organised by PACE-CME - Supported by an unrestricted educational grant from Amarin Pharma
Event: ESC Congress 2022

Congress Presentation

About the speaker

Professor Magnus Back

Karolinska University Hospital, Stockholm (Sweden)
8 presentations
0 follower

4 more presentations in this session

Introduction.

Speaker: Professor L. Badimon (Barcelona, ES)

Access
Slides
Video
Thumbnail

ASCVD & residual risk: recent clinical insights with icosapent ethyl.

Speaker: Professor D. Bhatt (New York, US)

Access
Slides
Video
Thumbnail

Integrating icosapent ethyl in clinical practice: which patients will benefit?

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Thumbnail

Discussion.

Speaker: Professor L. Badimon (Barcelona, ES)

Access
Slides
Video
Thumbnail

Access the full session

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Speakers: Professor M. Back, Professor L. Badimon, Professor D. Bhatt, Professor S. Verma, Professor L. Badimon
Access
Video
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb